Levodopa and Carbidopa
(Redirected from Levodopa-Carbidopa)
| Drug monograph · NCLEX study reference | |
| Trade names | Sinemet |
|---|---|
| Therapeutic class | Antiparkinson |
| Pharmacologic class | Dopamine precursor with decarboxylase inhibitor |
| Onset / peak / duration | Onset within days to weeks; ER smooths fluctuations. |
| Half-life / level | Short levodopa half-life; level not routine. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | None; supportive care. |
| Pregnancy / lactation | Use only if essential. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Levodopa and Carbidopa (brand name Sinemet) — Antiparkinson; Dopamine precursor with decarboxylase inhibitor.
Identification
- Therapeutic class: Antiparkinson.
- Pharmacologic class: Dopamine precursor with decarboxylase inhibitor.
Pharmacology
- Mechanism of action: Levodopa converts to dopamine in the brain; carbidopa prevents peripheral breakdown, increasing central delivery and reducing nausea.
- Onset / peak / duration: Onset within days to weeks; ER smooths fluctuations.
- Half-life / therapeutic level: Short levodopa half-life; level not routine.
Clinical use
- Indications: Parkinson disease.
- Usual dose, route, frequency: Titrated PO three or more times daily.
- Maximum dose / adjustments: Titrate to motor response; avoid abrupt withdrawal.
Safety
- Contraindications: Narrow-angle glaucoma, MAO inhibitor use within 14 days, melanoma history caution.
- Black box warning: None.
- Interactions: Nonselective MAO inhibitors (hypertensive crisis), high-protein meals reduce absorption (food), antipsychotics oppose effect, iron reduces absorption.
- Pregnancy / lactation: Use only if essential.
- High-alert: No.
Adverse effects
- Common side effects: Nausea, orthostatic hypotension, dyskinesias, darkened urine or sweat.
- Serious effects to report: On-off motor fluctuations, hallucinations, impulse-control behaviors, dyskinesia.
- Antidote / reversal: None; supportive care.
Nursing process
- Assessment before administration: Motor status, blood pressure, mental status.
- Interventions during therapy: Separate from high-protein meals; rise slowly; do not stop abruptly.
- Monitor: Motor function, blood pressure, mood and behavior.
- Evaluation / expected outcome: Improved tremor, rigidity, and movement.
Patient teaching
- Patient teaching: Effect may wear off between doses; report compulsive behaviors; harmless darkening of urine or sweat.
- Notify provider if: Hallucinations, uncontrolled movements, fainting, gambling or other impulses.
- Administration tips: Consistent timing; limit protein near doses.